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Abstract
Six different somatic missense mutations in the human ADAM12 gene have been identified so far in breast cancer. Five of
these mutations involve highly conserved residues in the extracellular domain of the transmembrane ADAM12-L protein.
Two of these extracellular mutations, D301H and G479E, have been previously characterized in the context of mouse
ADAM12. Three other mutations, T596A, R612Q, and G668A, have been reported more recently, and their effects on
ADAM12-L protein structure/function are not known. Here, we show that ADAM12-L bearing the G668A mutation is largely
retained in the endoplasmic reticulum in its nascent, full-length form, with an intact N-terminal pro-domain. The T596A and
R612Q mutants are efficiently trafficked to the cell surface and proteolytically processed to remove their pro-domains.
However, the T596A mutant shows decreased catalytic activity at the cell surface, while the R612Q mutant is fully active and
comparable to the wild-type ADAM12-L. The D301H and G479E mutants, consistent with the corresponding D299H and
G477E mutants of mouse ADAM12 described earlier, are not proteolytically processed and do not exhibit catalytic activity at
the cell surface. Among all six breast cancer-associated mutations in ADAM12-L, mutations that preserve the activity -
R612Q and L792F - occur in triple-negative breast cancers, while loss-of-function mutations - D301H, G479E, T596A, and
G668A - are found in non-triple negative cancers. This apparent association between the catalytic activity of the mutants
and the type of breast cancer supports a previously postulated role of an active ADAM12-L in the triple negative breast
cancer disease.
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Introduction
Disintegrin and metalloproteinase domain-containing protein
ADAM12 is a member of the ADAM family of proteins that
mediate cleavage of substrates at the cell surface and/or modulate
intracellular signaling pathways [1,2]. ADAM12 is highly up-
regulated in human breast tumors [3–9]. In triple negative breast
cancers (TNBCs, lacking estrogen receptor and progesterone
receptor expression and ERBB2 gene amplification), high expres-
sion of ADAM12-L, but not ADAM12-S, mRNA is associated with
poor prognosis [10]. ADAM12-L and ADAM12-S are two different
splice variants that encode the long, transmembrane protein
isoform ADAM12-L and the short, secreted ADAM12-S, respec-
tively [11].
Among thirteen different ADAM genes that encode catalytically
active proteases [1], ADAM12 is the most frequently somatically
mutated gene in human breast cancers. As of September 2013, the
COSMIC database (Catalogue of Somatic Mutations in Cancer,
http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) list-
ed 6 confirmed somatic missense mutations in the ADAM12 gene
per a total of 1104 unique breast carcinoma samples analyzed.
The frequencies of breast cancer-associated missense mutations in
other genes encoding catalytically active ADAMs were: 1/973 in
ADAM9, 1/973 in ADAM10, 1/1147 in ADAM17, 1/1010 in
ADAM19, 1/973 (plus one nonsense mutation) in ADAM20, and
1/973 in ADAM30. No other missense/nonsense somatic muta-
tions were reported for the remaining ADAM genes encoding
catalytically active proteases (i.e., ADAM8, 215, 221, 228, 233,
and ADAMDEC1). A relatively high frequency of mutations in the
ADAM12 gene can be attributed to the fact that ADAM12 is
located on human chromosome 10q26.2, in a region capable of
forming highly stable secondary structures [12].
The six breast cancer-associated mutations in the ADAM12-L
protein include the D301H mutation in the metalloproteinase
domain, G479E in the disintegrin domain, T596A and R612Q in
the cysteine-rich domain, G668A in the epidermal growth factor
(EGF)-like domain, and L792F in the cytoplasmic tail [13–15]
(Figure 1A). We have previously shown that the D299H and
G477E mutations in mouse ADAM12 (which correspond to the
D301H and G479E mutations in human ADAM12) are loss-of-
function mutations that inhibit the intracellular trafficking and
proteolytic activation of the nascent ADAM12 protein [16]. The
L792F mutation in human ADAM12-L was reported not to affect
protein processing, localization, or function [16,17]. The other
three mutations - T596A, R612Q, and G668A - have been
identified more recently [14,15], and their effects on the structure/
function of ADAM12 are currently unknown.
Here, we show that there is functional diversity between the
three recently identified mutations. While ADAM12-L containing
the G668A mutation is largely retained in the endoplasmic
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reticulum (ER) and is not proteolytically activated in the Golgi, the
T596A mutant is properly trafficked and proteolytically processed
but is still catalytically inactive. The R612Q mutant is trafficked,
processed, active, and is indistinguishable from the wild-type (WT)
ADAM12-L. Taking into consideration all six known breast
cancer-associated somatic mutations in ADAM12-L, we note an
apparent association between the catalytic activity of ADAM12-L
mutants and the molecular characteristic of the tumor. The two
mutations that do not have any effect on ADAM12-L activity,
R612Q and L792F, occurred in TNBCs. The four mutations that
render ADAM12-L inactive, i.e., D301H, G479E, G668A, and
T596A, were described in non-TNBCs. This observation further
suggests an important role of the catalytically active ADAM12-L
in the triple negative breast cancer disease.
Materials and Methods
Expression Constructs
Retroviral expression vector ADAM12-L-pBABEpuro was used
for the expression of the wild-type (WT) ADAM12-L protein. The
D301H, G479E, T596A, R612Q and G668A point mutations
were introduced by site-directed mutagenesis using the Quick-
Change kit (Stratagene). The entire lengths of all DNA inserts
were sequenced to confirm that no other mutations were
introduced during mutagenesis. The expression construct of
Delta-like 1 (DLL1) in pIRESpuro vector was described earlier
[18].
Cell Culture and Treatment
Human MCF10A mammary epithelial cells (ATCC) were
cultured in DMEM/F12 (1:1) supplemented with 5% horse serum,
0.5 mg/ml hydrocortisone, 20 ng/ml human EGF, 10 mg/ml
insulin, 100 ng/ml cholera toxin, and 1% penicillin/streptomycin.
Retrovirus production and stable transduction of MCF10A cells
with viruses encoding WT or mutant ADAM12-L, or with control
viruses bearing empty pBABEpuro vector, were performed as
described previously [19]. Transient transfections were performed
using X-tremeGENE HP transfection reagent (Roche). For protein
stability assay, cells were treated with 10 mg/ml cycloheximide
(EMD Millipore) in culture medium for indicated times.
Antibodies
Anti-ADAM12 rabbit polyclonal antibody (Ab 3394) specific for
the cytoplasmic domain of human ADAM12-L was developed in
our laboratory, as described [10]. The remaining antibodies were:
anti-ADAM12 mouse mAb (R&D Systems; clone 632525, specific
for the extracellular domain of ADAM12-L), anti-KDEL mouse
mAb (clone 10C3, Enzo Life Sciences), anti-EGFR (D38B1) XP
rabbit mAb (Cell Signaling), anti-phospho-EGFR (pY1173) rabbit
polyclonal Ab (R&D Systems), anti-DLL1 rabbit polyclonal Ab
(H-265, Santa Cruz Biotechnology), anti-b-actin mouse mAb
(clone AC-15, Sigma), and anti-a-tubulin mouse mAb (clone DM
1A, Sigma).
Immunofluorescence
Stably transduced MCF10A cells were plated on glass coverslips
placed in 6-well plates. Two days later, cells were fixed with 3.7%
paraformaldehyde/DPBS for 20 min, followed by permeabiliza-
tion with 0.1% Triton X-100/DPBS for 5 min. Coverslips were
incubated with anti-ADAM12-L polyclonal antibody (1:500
dilution) and anti-KDEL antibody (1:200 dilution), followed by
incubation with rhodamine Red-X-conjugated anti-rabbit IgG
antibody, Alexa 488-conjugated anti-mouse IgG antibody, and
DAPI. Immunofluorescence was examined using an Axiovert 200
inverted fluorescent microscope.
Flow Cytometry
Cells were trypsinized into a single cell suspension, washed with
DPBS containing 3% BSA, and incubated with anti-ADAM12
monoclonal antibody or isotype control antibody (R&D Systems,
both at 1:10 dilution) for 30 minutes on ice. Cells were then
washed 3 times, incubated with allophycocyanin (APC)-conjugated
anti-mouse antibodies (Jackson ImmunoResearch; 1:100) for
30 min on ice, washed again, and then incubated with 1 mg/ml
propidium iodide (PI; BD Biosciences) for viability. Analysis was
performed using a BD FACSCalibur flow cytometer. Only the
cells negative for PI staining (viable cells) were selected for the
ADAM12 analysis.
Cell Surface Biotinylation and Western Blotting
Cells were washed with DPBS, incubated for 60 min at 4uC
with 2.5 mM EZ-link NHS-PEG12-biotin (Thermo Scientific), and
then washed with ice-cold 100 mM glycine/DPBS. Cellular
proteins were extracted with extraction buffer (50 mM Tris-HCl,
pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% sodium deoxy-
cholate, 0.1% SDS, 1 mM 4-(2-aminoethyl)-benzene-sulfonyl-
fluoride hydrochloride (AEBSF), 5 mg/ml aprotinin, 5 mg/ml
leupeptin, 5 mg/ml pepstatin A, 10 mM 1,10-phenanthroline;
0.5 ml buffer/well in a 6-well plate). Cell extracts were centrifuged
at 21,0006g for 15 min at 4uC, and supernatants were incubated
for 1 h at 4uC with NeutrAvidin sepharose (GE Healthcare;
0.5 ml cell extract/25 ml of resin). The resin was washed three
times with extraction buffer, eluted with SDS sample buffer;
samples were then resolved by SDS-PAGE and transferred to a
nitrocellulose membrane. Western blotting was performed using
anti-ADAM12 polyclonal (1:20,000 dilution), anti-DLL1 (1:1,000),
anti-EGFR (1:5,000 dilution), anti-pY1173 EGFR (1:5,000)
primary antibodies and HRP-conjugated secondary antibodies,
as described [10]. Signal detection was performed using WestPico
chemiluminescence detection kit (Pierce).
Endo H Treatment
Stably transduced cells were treated with extraction buffer and
centrifuged at 21,0006g for 15 min at 4uC. Supernatants were
treated with EndoHf denaturing buffer (New England BioLabs),
boiled, and then treated with Endo Hf (3,000 U), according to the
manufacturer’s instructions.
Determination of Cell Doubling Times
Stably transduced cells were seeded in 6-well plates at the
density of 60,000 cells/well. After 24, 48, and 72 h, cells were
detached and counted with Cellometer AutoT4 (Nexcelom
Bioscience), in duplicates. Exponential growth curves were fitted
to each dataset and the doubling times were calculated using a
nonlinear regression function in the GraphPad Prism 5.0 software.
Evaluation of ADAM12-L-mediated Shedding of EGFR
Ligands
MCF10A cells stably overexpressing WT or mutant ADAM12-
L proteins, or cells stably transduced with empty pBABEpuro
vector, were incubated for 16 h in serum-free media. Conditioned
media were then collected, pre-cleared by centrifugation, and
added to the duplicate wells containing ‘‘reporter’’ empty vector-
transduced MCF10A cells that were pre-incubated for 16 h in
serum-free medium. After 30 min, cells were washed with DPBS,
treated with extraction buffer containing phosphatase inhibitors
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Figure 1. Breast cancer-associated mutations in human ADAM12-L. (A) A diagram of human ADAM12-L. Six non-synonymous mutations
identified in human breast cancers are indicated. S, signal peptide; P, prodomain; M, metalloproteinase domain; D, disintegrin domain; C, cysteine-rich
domain; E, EGF-like domain; T, transmembrane region; Cyt, cytoplasmic tail. (B) Model of the extracellular domain of human ADAM12-L generated by
the I-TASSER protein structure prediction tool (C-score 20.26, estimated TM accuracy of the model 0.6860.12 [20,21]). The metalloproteinase,
disintegrin, cysteine-rich, and EGF-like domains are shown in purple, blue, yellow, and green, respectively. Positions of the five amino acids mutated
in breast cancers (red spheres) and the side chain of the catalytic residue E351 (cyan sticks) are indicated. (C) Sequence alignment of the cysteine-rich
and EGF-like domains of ADAM12 from different species. NCBI RefSeq numbers are: Homo_sapiens, NP_003465; Mus_musculus, NP_031426;
ADAM12 Mutations in Breast Cancer
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50 mM NaF, 2 mM Na3VO4, and 10 mM Na4P2O7, and
analyzed by SDS-PAGE and Western blotting using anti-
phospho-EGFR (pY1173) and anti-EGFR antibodies.
Cell Migration Assay
MCF10A cells with stable overexpression of WT or mutant
ADAM12-L proteins, or control empty vector-transduced cells,
were suspended in MCF10A medium containing 0.1% BSA
instead of horse serum, and seeded in the upper chambers of
Transwell inserts with a 8-mm pore size polyethylene terephthalate
membrane (BD Biosciences), at 2.56104 cells/chamber. The lower
chambers contained the full culture medium supplemented with
5% horse serum and 20 ng/ml EGF. After incubation at 37uC for
18 h, cells were fixed with 3% glutaraldehyde in DPBS for 20 min,
washed twice with DPBS, and stained with 0.5% crystal violet in
20% methanol for 10 min. Cells at the upper face of the
membrane were removed with cotton swabs, and cells at the
lower face were examined with an inverted microscope using a
106 magnification, and photographed. Numbers of cells in five
random fields were counted, and the mean number of migrated
cells for each insert was determined.
ADAM12-L Structure Prediction
The I-TASSER software (http://zhanglab.ccmb.med.umich.
edu/I-TASSER/, refs. [20,21]) was used to predict the structure of
the extracellular domain of the mature form of human ADAM12-
L (amino acids 208–708). The ADAM22 template (PDB:3G5C)
was excluded from the I-TASSER template library due to a
compact packing of the metalloproteinase domain against the
cysteine-rich domain and steric hindrance of the pseudo-catalytic
site [22], a feature that may be characteristic for catalytically
inactive ADAMs.
Statistical Analysis
Fisher’s exact test, unpaired t test, and linear regression were
performed using GraphPad Prism 5.0.
Results
The five breast cancer-associated mutations mapping to the
extracellular portion of ADAM12-L are located in different
domains and spread over a region spanning more than 300
amino acids (Figure 1A). We asked whether these mutations might
be clustered in a particular region in the three-dimensional
structure of the protein. Since the X-ray structure of human
ADAM12-L is not available, we used the I-TASSER protein
structure prediction tool [20,21] to build a 3D model of the
extracellular domain of the active form of human ADAM12-L
comprising the metalloproteinase, disintegrin, cysteine-rich, and
EGF-like domains. From the model, it is apparent that the cancer-
associated mutations are scattered over the entire structure and
they do not cluster in a particular region of the protein (Figure 1B).
The three recently identified mutations - T596A, G668A, and
R612Q - involve amino acid residues in ADAM12 that are highly
conserved between species (Figure 1C). The G668 residue is also
conserved between human ADAM12 and the most closely related
human ADAMs, namely ADAM19, ADAM33, and ADAM15 [1].
In contrast, the T596 and R612 residues are not conserved
between ADAM12-L and the other three ADAMs (Figure 1D). To
study the effects of the T596A, G668A, and R612Q mutations on
the functionality of ADAM12-L, we stably expressed WT and
mutated ADAM12-L proteins in human MCF10A mammary
epithelial cells. Western blotting of total cell lysates with an
antibody specific for the cytoplasmic tail of ADAM12-L demon-
strated that the proteolytic processing of WT ADAM12-L and the
T596A and R612Q mutants was virtually indistinguishable
(Figure 2A). In all three cases, the mature, processed form of
,90-kDa was easily detected, and its abundance was similar to
that of the nascent, full-length form of ,120-kDa. In contrast,
processing of the G668A mutant was significantly inhibited.
Staining of live cells with an antibody recognizing the extracellular
domain of ADAM12-L and analysis by flow cytometry demon-
strated that WT ADAM12-L and the T596A and R612Q mutants
were readily detected at the cell surface, whereas the G668A
mutant showed much weaker cell surface staining (Figure 2B). To
further explore the intracellular localization of WT ADAM12-L
and the mutants, we performed immunofluorescence staining of
permeabilized cells with anti-ADAM12 and anti-KDEL antibody,
a marker of the ER. We observed that substantial amounts of WT
ADAM12-L and the T596A and R612Q mutants were present in
post-ER compartments located at the cell periphery (Figure 2C),
consistent with cell surface localization of these proteins detected
by flow cytometry. In contrast, anti-ADAM12 staining in G668A-
expressing cells largely coincided with anti-KDEL staining
(Figure 2C), suggesting that this mutant was retained, at least
partially, in the ER and explaining why it was poorly detected at
the cell surface (Figure 2B).
The pronounced effect of the G668A mutation on the
processing and localization of ADAM12-L is unexpected, given
the very conservative nature of the Gly-to-Ala substitution. Thus,
the maturation of the G668A mutant in the secretory pathway was
further probed with endoglycosidase H (Endo H) and compared to
the WT ADAM12-L. When the lysate of WT-expressing cells was
treated with Endo H, the mobility of the nascent ADAM12-L
increased, while the mature form was more resistant to the Endo
H treatment (Figure 3A). This result indicated that the mature
form, but not the nascent form, progressed through the Golgi
compartment, where the resistance of N-linked oligosaccharides to
Endo H is acquired. The G668A mutant, represented predom-
inantly by the full-length form, was sensitive to Endo H, further
suggesting that this mutant did not efficiently progress beyond the
ER. Finally, we performed cell surface biotinylation of intact cells
expressing the WT or G668A mutant protein. In WT ADAM12-
L-expressing cells, the mature form was efficiently biotinylated,
whereas the nascent form was resistant to the modification
(Figure 3B). This result indicated that at the cell surface of WT
ADAM12-L-expressing cells, the mature ADAM12-L form was
much more abundant than the nascent form. In G668A mutant-
expressing cells, the extent of cell surface biotinylation of
ADAM12-L was considerably lower than in WT ADAM12-
expressing cells, further indicating that the G668A mutation
impaired trafficking of the ADAM12-L protein to the cell surface.
The next question might be: Why is the G668A mutant
inefficiently trafficked to the cell surface and predominantly
retained in the ER? We reasoned that this mutant might be
misfolded and retained by the protein quality control system
Rattus_norvegicus, XP_001054670; Bos_taurus, NP_001001156, Equus_caballus, XP_001490097; Gallus_gallus, NP_001136322, and Xenopus_tropicalis,
NP_001035103. (D) Sequence alignment of the cysteine-rich and EGF-like domains of human ADAM12 and the most closely related human ADAMs.
NCBI RefSeq numbers are: ADAM19, XP_005266060, ADAM33, NP_079496.1, and ADAM15, NP_997080. In C and D, asterisks indicate three novel
mutations in human ADAM12 found in breast tumors [14,15]. Clustal X color scheme was applied.
doi:10.1371/journal.pone.0092536.g001
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operating in the ER. However, using co-immunoprecipitation, we
did not detect interaction between the G668A mutant (or WT
ADAM12-L) with ER chaperones BiP, Grp94, and calnexin, or
with ER stress proteins that assist in proper disulfide formation
ERp44, ERp57, ERp72, Ero1, PDI (results not shown). Also,
cellular levels of these chaperones/stress proteins were not
Figure 2. The effect of G668A, T596A, and R612Q mutations on the proteolytic processing and intracellular localization of
ADAM12-L. (A) Proteolytic processing of the WT and mutant forms of human ADAM12-L in MCF10A cells. Cells with stable expression of ADAM12-L
proteins or control empty vector (EV)-transduced cells were selected with puromycin after retroviral infection. Total cell lysates were analyzed by
Western blotting using antibody specific for the cytoplasmic tail of ADAM12-L. Arrowhead indicates the nascent, full-length, catalytically inactive
form, and arrow denotes the mature, processed, catalytically active form of ADAM12-L. (B) Cell surface localization of ADAM12-L was examined by
flow cytometry. Live cells were trypsinized and stained with an antibody specific for the extracellular domain of ADAM12-L (red) or with isotype
control antibody (black). (C) Intracellular localization of the WT and mutant ADAM12-L proteins. Cells were co-stained with anti-ADAM12 antibody
(red), anti-KDEL antibody (endoplasmic reticulum marker; green), and DAPI (blue). Control represents cells expressing WT ADAM12-L, incubated with
pre-immune serum instead of anti-ADAM12 antibody. Arrows indicate ADAM12 staining in post-ER compartments. Bar, 20 mm.
doi:10.1371/journal.pone.0092536.g002
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elevated in G668A-expressing cells. Cycloheximide chase exper-
iments further demonstrated that the G668A mutant was in fact
more stable than the WT ADAM12-L protein. Estimated half-life
of the G668A mutant was 5.9 h, which was significantly larger
than the half-life of WT ADAM12-L (3.3 h, Figure 3C). Collec-
tively, these results suggested that although the G668A mutant was
retained in the ER, most likely it was not misfolded and it was not
subject to rapid degradation.
Next, we asked about the catalytic activity of ADAM12-L
mutants. While a mutation causing impaired intracellular traffick-
ing of ADAM12-L is naturally expected to cause a decrease in the
enzyme activity at the cell surface (unless it exerts an indirect
effect, such as enhancing cell surface expression of a different
proteolytic enzyme), a mutation that does not affect intracellular
trafficking and processing can still have an impact on the catalysis
or substrate recognition. For comparison, we also included the
D301H and G479E mutants in the current analysis. The
corresponding D299H and G477E mutations in mouse ADAM12
were shown previously to block the intracellular trafficking and
processing of the protein, as well as ADAM12-mediated cleavage
of the substrate protein DLL1 [16]. Trafficking, processing, and
catalytic activities of human D301H or G479E mutants have not
been examined before. The L792F mutation in the cytoplasmic
tail of human ADAM12-L was reported to have no effect on
ADAM12-L trafficking, processing, or catalytic activity [16,17].
We used three different approaches to evaluate the catalytic
activity of the D301H, G479E, T596A, R612Q, and G668A
mutants at the surface of MCF10A cells (Figure 4A). In the first
approach, cells with stable overexpression of WT or mutant
ADAM12-L were transfected with a plasmid encoding DLL1. The
full-length (FL) DLL1 and the C-terminal fragment (CTF)
generated by the proteolytic cleavage were detected by Western
blotting, as described previously [16,18]. We observed that the
CTF/FL ratio of DLL1 was higher in cells expressing WT
ADAM12-L or the R612Q mutant than in control cells, indicative
of the catalytic activity of these ADAM12 proteins toward the
DLL1 substrate (Figure 4B). In contrast, the CTF/FL ratio was
not increased in D301H, G479E, G668A, or T596A mutant-
expressing cells compared to control cells, suggesting that these
four mutations significantly reduced the ability of ADAM12-L to
cleave DLL1.
In the second approach, we focused on ADAM12-L-mediated
shedding of EGFR ligands, as this function of ADAM12-L has
been recently shown to be important in the biology of TNBC [10].
Among different EGFR ligands, ADAM12-L was previously
shown to cleave EGF [23,24] and heparin-binding(HB)-EGF
[25,26]. Here, the amount of endogenous EGFR ligands shed to
the media by MCF10A cells stably overexpressing WT or mutant
ADAM12-L proteins was evaluated. Cells were incubated for 16 h
in serum-free media, the conditioned media were then transferred
to starved ‘‘reporter’’ MCF10A cells, incubated for 30 min, and
then the extent of EGFR phosphorylation at Tyr1173, one of the
major autophosphorylation sites in response to ligand binding
[27], was examined. Conditioned media from WT ADAM12-L or
R612Q mutant-expressing cells increased EGFR phosphorylation
in reporter cells (Figure 4C). In contrast, conditioned media from
D301H, G479E, G668A, or T596A mutant-expressing cells did
not cause elevation in EGFR phosphorylation (Figure 4C),
suggesting that these mutants most likely did not efficiently shed
EGFR ligands.
In the third approach, we investigated the effect of WT and
mutant ADAM12-L expression on cell migration. We showed
Figure 3. The G668A mutation causes retention of ADAM12-L in the endoplasmic reticulum. (A) Probing the maturation of ADAM12-L
proteins in post-ER compartments by treatment with endoglycosidase H (Endo H). Total cell lysates were incubated for 1 h with Endo H, followed by
Western blotting with anti-ADAM12 antibody. Asterisk indicates the full-length, de-glycosylated form of ADAM12-L. (B) Cell surface biotinylation of
ADAM12-L proteins. Intact cells were incubated for 1 h with membrane-impermeable NHS-PEG12-biotin, followed by isolation of biotinylated proteins
using NeutrAvidin beads and Western blotting with anti-ADAM12 antibody. Input (In) refers to total cell lysates prior to Neutravidin binding, and
eluate (El) refers to biotinylated proteins that bound to the resin. Biotinylation of epidermal growth factor receptor (EGFR) served as positive control.
(C) Protein stability assay. Cells were incubated with 10 mg/ml of cycloheximide for the indicated times, followed by immunoblotting. Band intensities
of ADAM12-L (nascent and mature forms combined) were quantified by densitometry, normalized to b-actin, and analyzed using a single exponential
decay model. Half-lives of the WT and the G668A mutant ADAM12-L were significantly different (3.3 h vs 5.9 h, respectively, P= 0.0031).
doi:10.1371/journal.pone.0092536.g003
ADAM12 Mutations in Breast Cancer
PLOS ONE | www.plosone.org 6 March 2014 | Volume 9 | Issue 3 | e92536
previously that overexpression of mouse ADAM12 in NIH3T3
cells increased cell migration using scratch wound assay, and that
the D299H and G477E mouse ADAM12 mutants were inactive
[16]. ADAM12-L has been also found to potentiate the migration
of head and neck squamous cell carcinoma cells [28]. However,
overexpression of ADAM12-L in breast cancer MCF-7 cells did
not affect cell migration [29], and mouse ADAM12 was reported
to inhibit keratinocyte migration or integrin a4b1-mediated CHO
cell migration cells [30,31]. Thus, the effect of ADAM12 on cell
migration appears to be highly context-dependent and may
involve distinct mechanisms. In the current study, we used a
Transwell assay to assess the effect of mutations in human
ADAM12-L on the migration of MCF10A cells. While overex-
pression of WT ADAM12-L or the mutants did not affect cell
growth (Figure 5A), the WT and the R612Q mutant ADAM12-L
significantly increased cell migration (Figure 5B and C). This up-
regulation of cell migration required the catalytic activity of
ADAM12-L, because the E351Q mutant-expressing cells migrated
at a rate similar to control cells. Importantly, overexpression of the
D301H, G479E, G668A, or T596A mutants did not increase cell
migration, further indicating that these mutants were either not
efficiently targeted to the cell surface or had activities significantly
lower than the WT ADAM12-L and the R612Q mutant.
A summary of the functional characterization of breast-cancer
associated ADAM12-L mutations, as well as the properties of
breast tumors in which each mutation was identified, is provided
in Table 1. Included in Table 1 are also SIFT scores and PolyPhen
scores obtained from the Ensembl Genome Browser (www.
ensembl.org). SIFT is a sequence homology-based tool that sorts
intolerant from tolerant amino acid substitutions and predicts
whether an amino acid substitution in a protein will have a
phenotypic effect (http://sift.jcvi.org, ref. [32]). PolyPhen-2 is a
tool which predicts the variation effect on protein function based
on physical and comparative considerations (http://genetics.bwh.
harvard.edu/pph2; ref. [33]). SIFT scores #0.05 and PolyPhen
scores $0.95 designate amino acid substitutions that are predicted
to be damaging to the structure/function of a protein. As
summarized in Table 1, with the exception of the T596A
mutation, there is an agreement between the predicted effect of
each mutation and the experimentally determined activity of
Figure 4. Cell-based assays of the catalytic activity of ADAM12-L mutants. (A) MCF10A cells with stable overexpression of WT or mutant
ADAM12-L proteins, or control empty vector (EV)-transduced cells used in assays shown in panels B and C. The E351Q mutant is catalytically inactive
due to the mutation at the active site and is used as negative control. (B) Cells shown in panel A were transiently transfected to express a substrate
protein Delta-like 1 (DLL1). Cell extracts were subjected to Western blotting with anti-DLL1 antibody. The full-length (FL) DLL1 and the C-terminal
fragment (CTF) generated by the proteolytic cleavage are indicated. Band intensities were quantified by densitometry. The experiment was repeated
two times, mean values6 SEM are shown. *, P,0.05. Notice that the amount of the C-terminal fragment (CTF) of DLL1 is increased in WT- and R612Q
mutant ADAM12-L-expressing cells. (C) Cells shown in panel A were serum-starved for 16 h. Conditioned media were then transferred to reporter
MCF10A cells that were also pre-starved for 16 h, and incubation continued for 30 min. The level of phosphorylation of EGFR in reporter cells was
evaluated by Western blotting using anti-phosho-Y1173 antibody, band intensities were quantified by densitometry, and the extent of
phosphorylation of EGFR (pEGFR) normalized to the total EGFR protein was evaluated. Conditioned media from EV-transduced cells supplemented
with 15 ng/ml EGF served as positive control. The experiment was repeated three times, mean values 6 SEM are shown. *, P,0.05. Notice that EGFR
phosphorylation in reporter cells was increased upon adding conditioned media from WT- or R612Q mutant ADAM12-L-expressing cells.
doi:10.1371/journal.pone.0092536.g004
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ADAM12-L. Importantly, mutations that do not have impact on
the ADAM12-L activity - R612Q and L792F - were found in
TNBCs. Mutations that inhibit the ADAM12-L activity - D301H,
G479E, G668A, and T596A - occurred in non-TNBCs. Thus,
there is an apparent association between the intact activity of
ADAM12-L and the triple-negative status of tumors, although this
association is only borderline significant due to the small sample
size (P=0.0667, Fisher’s exact test).
Figure 5. The effect of WT and mutant ADAM12-L on cell
growth and migration. (A) Doubling times of MCF10A cells with
stable overexpression of WT or mutant ADAM12-L proteins, or control
empty vector (EV)-transduced cells. The data are shown as means with
95% confidence intervals based on 3 independent determinations. (B)
Cells were analyzed for migration using Transwell assays. Representa-
tive images of crystal violet-stained cells present at the lower face of the
Transwell inserts are shown. (C) Quantification of the migration assay.
The numbers of migrated cells were counted in five random fields for
each insert. The data are shown as mean 6 SEM from 3 determinations.
*, P,0.05.
doi:10.1371/journal.pone.0092536.g005
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Discussion
The current study, together with two other previous reports
[16,17], provides an insight into the structural/functional aspects
of the currently known breast cancer-associated mutations in
ADAM12. These mutations are scattered along the entire length
of the protein, and they do not appear to cluster within a specific
region in the three-dimensional model of ADAM12-L. Among
three novel mutations characterized for the first time in this study,
only one - G668A - has a severe impact on the intracellular
trafficking and proteolytic processing of the protein. Considering
the very conservative nature of the Gly-to-Ala substitution, this
finding is somewhat unexpected. However, as Gly is highly flexible
and can adopt conformations that are forbidden for other amino
acids, it is possible that the replacing Gly with Ala at position 668
is not compatible with the native structure of ADAM12-L. High
conservation of Gly668 between ADAM12-L and other related
ADAMs (Figure 1D) further suggests the importance of a Gly
residue at this position.
The G668A mutation adds to the other two mutations that were
previously found to cause ER retention and a lack of proteolytic
processing of mouse ADAM12, and are now confirmed to inhibit
the processing of human ADAM12-L, i.e., D301H and G479E.
While we do not find any evidence that these mutants are unfolded
and rapidly degraded, they must assume a significantly different
conformation from the WT ADAM12-L to be retained in the ER.
Clearly, since these three mutants exist mostly as the ,120-kDa
precursors, with the inhibitory pro-domain intact, they are
expected to be catalytically inactive. The lack of catalytic activity
of the D301H, G479E, and G668A mutants has been confirmed
here by the DLL1 cleavage assay, by the EGFR activation assay,
and by the Transwell migration assay.
The effects of D301H, G479E, and G668A mutations on the
structure/function of ADAM12-L agree well with the effects
predicted by the SIFT and PolyPhen tools (see Table 1).
Interestingly, the T596A mutation is predicted to be tolerated by
SIFT, but harmful by the PolyPhen-2 algorithm. We find that the
T596A substitution does not affect intracellular processing of
ADAM12, and this result is consistent with the fact that with
Thr596 is poorly conserved between ADAM12-L and other
closely related human ADAMs (Figure 1D). However, we find that
the T596A mutation renders ADAM12-L inactive at the cell
surface. Thr596 is not located at the active site and most likely it is
positioned distantly from the metalloproteinase domain in the
three-dimensional structure of ADAM12 (Figure 1B). It is
currently unclear whether the T596A substitution exerts a long-
range inhibitory effect on the catalytic site or whether it blocks the
interaction of ADAM12-L with its substrates. Overall, we
conclude that the D301H, G479E, T596A, and G668A mutations
should be classified as loss-of-function mutations.
The most striking observation emerging from this study is the
apparent association between the catalytic activity of ADAM12-L
mutants and the type of breast cancer. Two mutations that did not
have any impact on the catalytic activity of ADAM12-L, R612Q
and L792F, were found in triple-negative tumors. In contrast, all
four loss-of-function mutations, D301H, G479E, T596A, and
G668A, occurred in non-triple-negative tumors. Thus, it appears
that loss-of-function mutations in ADAM12-L tend to be excluded
from TNBCs. However, a larger patient population and possibly a
broader mutation spectrum are needed to test whether there is
indeed a significant association between the type of ADAM12-L
mutations and the triple-negative status of breast tumors.
Interestingly, the ADAM12 gene is located in the genomic region
that has been recently found to be significantly deleted in Luminal
B tumors (cytoband 10q26.11, wide peak boundaries
chr10:104674916-135534747, q value 0.0056373) [34]. Low q-
values associated with gene amplifications/deletions (typically
below 0.25) suggest that amplifications/deletions at a particular
locus are enriched by selective pressures [35]. The same study
found that the ADAM12 gene was hypermethylated and showed
lower expression in Luminal B tumors than in other types of breast
cancer [35]. As Luminal B tumors are estrogen receptor-positive
[36,37], these results, together with our functional analysis of
ADAM12 breast cancer-related mutants presented here, collec-
tively suggest that ADAM12 may play fundamentally different
roles in TNBCs and in non-TNBC.
We have recently postulated that ADAM12-L may be the
primary protease responsible for the activation of EGFR in early
stage, lymph node-negative TNBCs [10]. This conclusion was
supported by decreased distant metastasis-free survival times of
patients with high expression levels of ADAM12-L, increased
EGFR phosphorylation in a mouse xenograft model of breast
cancer, and a strong correlation between the level of anti-
ADAM12-L and anti-phospho-EGFR immunostaining in human
breast tumor samples. We have also noticed a positive correlation
between ADAM12-L and HB-EGF and EGFR in TNBCs, but not
in receptor-negative non-TNBCs [10]. In estrogen receptor-
positive MCF-7 breast cancer cells, overexpression of ADAM12-
L promoted estrogen-independent proliferation, and this effect of
ADAM12-L was linked to elevated EGFR activation [9].
Furthermore, a recent study demonstrated cancer cells under
hypoxia up-regulate ADAM12-L expression, leading to increased
HB-EGF shedding, EGFR activation, formation of invadopodia,
and cancer invasion [26]. We believe that these results, together
with the analysis of breast cancer-associated ADAM12-L mutants
described here, point to an important role of ADAM12-L in the
pathology of triple negative breast cancer.
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